UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence the achieved pharmaceutical products, has been granted in Israel. The patent provides protection until 2037 in this market.
“The continued expansion of our patent protection to include Israel follows other recent approvals in Japan and South Korea and further strengthens our commercial position in a wide range of markets across the world” says Nina Herne, CEO of LIDDS.
LIDDS has received patent approval in Israel for Patent Application 266008. The invention covering the production process for the NanoZolid® technology provides protection until 2037. Furthermore, the patent protects all pharmaceutical products obtained with the process described in the patent. This adds another important approval for this patent family, which has also received approvals in China, Russia, Australia, India, South Africa, Singapore, South Korea, and Japan in recent times. The patent and a related divisional patent are already approved in the US as previously communicated.